Summarized by Masters of Longevity from Longevity Technology.
Hemostemix will present its commercial-phase 1 longevity therapy at a virtual investor event.

Key Takeaways
- Hemostemix is presenting a commercial-phase 1 therapy.
- Thomas Smeenk is scheduled to speak at the event.
- The presentation has observational limits and is not causal.



